I agree that this site is using cookies. You can find further informations here.
X
Mukhopadhyay, Pralay
56  results:
Search for persons X
?
1

Comment on "Non-Proportional Hazards – an Evaluation of the..:

Lin, Ray S. ; Mukhopadhyay, Pralay ; Roychoudhury, Satrajit...
Statistics in Biopharmaceutical Research.  15 (2023)  2 - p. 312-314 , 2023
Link: https://doi.org/10.1080/..
 
?
2

Addressing the Impact of the COVID-19 Pandemic on Survival ..:

Ye, Jiabu ; Yu, Binbing ; Mann, Helen...
Journal of Data Science.  , 2022
Link: https://doi.org/10.6339/..
 
?
3

Correlation Between Early Endpoints and Overall Survival in..:

Shameer, Khader ; Zhang, Youyi ; Jackson, Dan...
Frontiers in Oncology.  11 (2021)  - p. , 2021
Link: https://doi.org/10.3389/..
 
?
4

Assessing the Influence of Subsequent Immunotherapy on Over..:

Ouwens, Mario ; Darilay, Annie ; Zhang, Yiduo...
Current Therapeutic Research.  95 (2021)  - p. 100640 , 2021
Link: https://doi.org/10.1016/..
 
?
5

Robust Design and Analysis of Clinical Trials With Nonpropo..:

Roychoudhury, Satrajit ; Anderson, Keaven M ; Ye, Jiabu.
Statistics in Biopharmaceutical Research.  15 (2021)  2 - p. 280-294 , 2021
Link: https://doi.org/10.1080/..
 
?
6

Optimal PD-L1–high cutoff for association with overall surv..:

Zajac, Magdalena ; Ye, Jiabu ; Mukhopadhyay, Pralay...
PLOS ONE.  15 (2020)  4 - p. e0231936 , 2020
Link: https://doi.org/10.1371/..
 
?
7

Alternative Analysis Methods for Time to Event Endpoints Un..:

Lin, Ray S. ; Lin, Ji ; Roychoudhury, Satrajit...
Statistics in Biopharmaceutical Research.  12 (2020)  2 - p. 187-198 , 2020
Link: https://doi.org/10.1080/..
 
?
8

Rejoinder to Letter to the Editor "The Hazards of Period Sp..:

Lin, Ray S. ; Lin, Ji ; Roychoudhury, Satrajit...
Statistics in Biopharmaceutical Research.  12 (2020)  4 - p. 520-521 , 2020
Link: https://doi.org/10.1080/..
 
?
9

Statistical and practical considerations in designing of im..:

Mukhopadhyay, Pralay ; Huang, Wenmei ; Metcalfe, Paul...
Journal of Biopharmaceutical Statistics.  30 (2020)  6 - p. 1130-1146 , 2020
Link: https://doi.org/10.1080/..
 
?
10

Relationship Between Progression‐Free Survival, Objective R..:

Ye, Jiabu ; Ji, Xiang ; Dennis, Phillip A...
Clinical Pharmacology & Therapeutics.  108 (2020)  6 - p. 1274-1288 , 2020
Link: https://doi.org/10.1002/..
 
?
11

Prognostic Significance of Liver Metastasis in Durvalumab-T..:

Sridhar, Sriram ; Paz-Ares, Luis ; Liu, Hao...
Clinical Lung Cancer.  20 (2019)  6 - p. e601-e608 , 2019
Link: https://doi.org/10.1016/..
 
?
12

Estimating Lifetime Benefits Associated with Immuno-Oncolog..:

Ouwens, Mario J. N. M. ; Mukhopadhyay, Pralay ; Zhang, Yiduo...
PharmacoEconomics.  37 (2019)  9 - p. 1129-1138 , 2019
Link: https://doi.org/10.1007/..
 
?
13

Patient‐reported outcomes and inflammatory biomarkers in pa..:

O'Donnell, Peter H. ; Arkenau, Hendrick Tobias ; Sridhar, Srikala S....
Cancer.  126 (2019)  2 - p. 432-443 , 2019
Link: https://doi.org/10.1002/..
 
?
14

Population Pharmacokinetics of Durvalumab in Cancer Patient..:

Baverel, Paul G. ; Dubois, Vincent F.S. ; Jin, Chao Yu...
Clinical Pharmacology & Therapeutics.  103 (2018)  4 - p. 631-642 , 2018
Link: https://doi.org/10.1002/..
 
?
15

Population Modeling of Tumor Kinetics and Overall Survival ..:

Zheng, Yanan ; Narwal, Rajesh ; Jin, ChaoYu...
Clinical Pharmacology & Therapeutics.  103 (2018)  4 - p. 643-652 , 2018
Link: https://doi.org/10.1002/..
 
1-15